INTANGIBLE ASSETS

The following table summarizes our intangible assets, net (in millions):



	March 31, 2019										December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment			Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir	$	10,720	$	(3,729	)	$	—		$	6,991	$	10,720	$	(3,554	)	$	—		$	7,166
Intangible asset - axicabtagene ciloleucel (DLBCL)	6,200		(502		)	—			5,698		6,200		(416		)	—			5,784
Intangible asset - Ranexa	688		(688		)	—			—		688		(678		)	—			10
Other	1,098		(387		)	(4		)	707		1,096		(359		)	(3		)	734
Total finite-lived assets	18,706		(5,306		)	(4		)	13,396		18,704		(5,007		)	(3		)	13,694
Indefinite-lived assets - In Process Research & Development	2,047		—			(5		)	2,042		2,047		—			(3		)	2,044
Total intangible assets	$	20,753	$	(5,306	)	$	(9	)	$	15,438	$	20,751	$	(5,007	)	$	(6	)	$	15,738

Aggregate amortization expense related to finite-lived intangible assets was $299 million and $301 million for the three months ended March 31, 2019 and 2018, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2019 (in millions):



Fiscal Year	Amount
2019 (remaining nine months)	$	851
2020	1,125
2021	1,125
2022	1,125
2023	1,125
Thereafter	8,045
Total	$	13,396